Powder preparation for tissue repair, method for producing the same, and injectable composition for tissue repair containing the same

Abstract

The present invention relates to a powder preparation for tissue repair and a method for producing the same, as well as an injectable composition for tissue repair containing the same. More specifically, the present invention relates to a powder preparation for tissue repair that is easy to transport, store and handle in powder form, is easily dissolved in an aqueous medium at room temperature to form stable nanoparticles, and, after being introduced into the body, induces collagen without being phagocytosed by macrophages, thereby exhibiting excellent tissue repair effects, as well as a method for producing the same, as well as an injectable composition for tissue repair containing the same.

Description

[Technical Field]

[0001] The present invention relates to a powder formulation for tissue repair, a method for producing the same, and an injectable composition for tissue repair containing the same. More specifically, the present invention relates to a powder formulation comprising a biocompatible copolymer that is a copolymer of a hydrophilic biocompatible polymer and a hydrophobic biocompatible polymer, and that forms micelle-shaped nanoparticles having an average diameter within a specific range in an aqueous medium, and / or in which the ratio of the molecular weight of the hydrophobic polymer to the molecular weight of the hydrophilic polymer is below a specific level. The powder formulation is easy to transport, store, and handle in powder form, dissolves easily in an aqueous medium at room temperature to form stable nanoparticles, and after being introduced into the body, induces collagen without being phagocytosed by macrophages, thereby exhibiting excellent tissue repair effects. The present invention also relates to a powder formulation and a method for producing the same, and an injectable composition for tissue repair containing the same. [Background technology]

[0002] Recently, more and more people are becoming interested in well-aging, or aging gracefully from a young age. It is no exaggeration to say that the current beauty market is focusing on anti-aging, which involves aging slowly, beautifully, and healthily. One of the most common signs of aging is loss of volume. In particular, lack of volume in the face can make people look older and shriveled, so there is growing interest in fillers that add volume. As a result, the filler market is growing rapidly year by year, currently accounting for a market worth more than 2 trillion won worldwide.

[0003] Currently, various filler materials are used, with hyaluronic acid fillers accounting for over 90% of the global filler market. However, they have a short half-life of one to three days in the body, a very short duration of release, and are absorbed very quickly. To address this issue, products that extend the absorption time by linking hyaluronic acid with a crosslinking agent are being sold. However, these crosslinked products involve the crosslinking agent BDDE (1,4-butanediol diglycidyl ether), which is a toxic carcinogen. Therefore, these crosslinked products face the problems of increased processing costs associated with the removal process, product disposal due to microbial contamination, and product disposal due to the detection of residues.

[0004] For this reason, numerous tissue repair products using biodegradable polymers have been developed. Conventional filler formulations using biocompatible polymers consist of water-insoluble polymers processed into microparticles and then dispersed in a viscous excipient or thickener. For example, formulations in which 20-50 micrometer diameter polylactic acid (PLA) particles are dispersed in a carboxymethylcellulose (CMC) aqueous solution, or 20-50 micrometer diameter polycaprolactone (PCL) particles are dispersed in a CMC and glycerin aqueous solution, have been used. However, these formulations have problems such as surgical inconvenient injection due to clogging of needles with microparticles and inconsistent particle dispersion, resulting in inconsistent tissue repair effects. Summary of the Invention [Problem to be solved by the invention]

[0005] The object of the present invention is to provide a tissue repair product and a method for producing the same, which is non-toxic, has functionality, physical properties and safety suitable for use as a tissue repair biomaterial, is easy to transport, store and handle, and exhibits excellent tissue repair effects. [Means for solving the problem]

[0006] In one aspect of the present invention, there is provided a powder preparation for tissue repair comprising a biocompatible copolymer which is a copolymer of a hydrophilic biocompatible polymer and a hydrophobic biocompatible polymer, (1) The biocompatible copolymer forms nanoparticles in the form of micelles having an average diameter of more than 20 nm and not more than 100 nm as measured by dynamic light scattering in an aqueous medium [Condition (1)]; or (2) The ratio (Mn1 / Mn2) of the number average molecular weight (Mn1) of the hydrophilic biocompatible polymer to the number average molecular weight (Mn2) of the hydrophobic biocompatible polymer in the biocompatible copolymer is 1.84 or less [condition (2)]; or (3) The present invention provides a powder preparation for tissue repair, wherein the biocompatible copolymer satisfies both of the above conditions (1) and (2).

[0007] Another aspect of the present invention is a method for producing a copolymer of a hydrophilic biocompatible polymer and a hydrophobic biocompatible polymer by polymerizing a monomer for a hydrophobic biocompatible polymer in the presence of a hydrophilic biocompatible polymer; and a step of drying the produced copolymer; (1) The biocompatible copolymer forms nanoparticles in the form of micelles having an average diameter of more than 20 nm and not more than 100 nm as measured by dynamic light scattering in an aqueous medium [Condition (1)]; or (2) The ratio (Mn1 / Mn2) of the number average molecular weight (Mn1) of the hydrophilic biocompatible polymer to the number average molecular weight (Mn2) of the hydrophobic biocompatible polymer in the biocompatible copolymer is 1.84 or less [condition (2)]; or (3) A method for producing a powder preparation for tissue repair, in which the biocompatible copolymer satisfies both of the above conditions (1) and (2).

[0008] Yet another aspect of the present invention provides an injectable composition for tissue repair, comprising the powder formulation for tissue repair of the present invention; and a pharmaceutically acceptable carrier for injection. Yet another aspect of the present invention provides a method for producing an injectable composition for tissue repair, which comprises mixing the powder formulation for tissue repair of the present invention and a pharmaceutically acceptable injectable carrier at room temperature. [Effects of the Invention]

[0009] The powder preparation for tissue repair according to the present invention is non-toxic, easy to transport, store, and handle, and easily dissolves in an aqueous medium at room temperature to form stable nanoparticles in the form of micelles with an average diameter of more than 20 nm to 100 nm in the aqueous medium. After being introduced into the body, the nanoparticles self-organize to form large structures due to the hydrophobic aggregation of hydrophobic polymers under the influence of the internal environment, and induce collagen without being phagocytosed by macrophages, thereby demonstrating excellent tissue repair effects. [Brief explanation of the drawings]

[0010] [Figure 1] FIG. 1 is a diagram showing the results of particle size measurement carried out in Experimental Example 2 of the present invention. [Figure 2] FIG. 10 shows the results of an animal experiment on the tissue repair effect in Experimental Example 4 of the present invention. BEST MODE FOR CARRYING OUT THE INVENTION

[0011] The present invention will now be described in more detail. The powder formulation for tissue repair of the present invention contains a biocompatible copolymer which is a copolymer of a hydrophilic biocompatible polymer and a hydrophobic biocompatible polymer. In one embodiment, the biocompatible copolymer forms nanoparticles in the form of micelles having an average diameter of more than 20 nm and not more than 100 nm as measured by dynamic light scattering in an aqueous medium [Condition (1)]. The aqueous medium may be, for example, water (more specifically, distilled water). Dynamic light scattering (DLS) is a well-established non-invasive technique for measuring nanoparticle size in a suspension. It utilizes the Brownian motion of particles to measure the intensity of scattered light over time in a suspension. The average particle diameter can be calculated by converting the fluctuations in scattered light intensity into the average particle diameter, which can then be calculated from the diffusion coefficient using the Stokes-Einstein equation.

[0012] If the average diameter (as measured by DLS) of the nanoparticles formed by the biocompatible copolymer in an aqueous medium is less than 20 nm or more than 100 nm, the powder formulation produced using such a copolymer may not exhibit tissue repair effects. More specifically, the average diameter of nanoparticles formed from the biocompatible copolymer in an aqueous medium (measured by DLS) may be, but is not limited to, greater than 20 nm, 21 nm or more, 25 nm or more, 30 nm or more, 35 nm or more, 40 nm or more, 45 nm or more, 50 nm or more, or 55 nm or more, or may be 100 nm or less, less than 100 nm, 95 nm or less, 90 nm or less, or 85 nm or less.

[0013] In another embodiment, in the biocompatible copolymer, the ratio (Mn1 / Mn2) of the number average molecular weight (Mn1) of the hydrophilic biocompatible polymer to the number average molecular weight (Mn2) of the hydrophobic biocompatible polymer is 1.84 or less [condition (2)]. The number average molecular weights of the hydrophilic and hydrophobic biocompatible polymers can be measured, for example, by gel permeation chromatography (GPC). Gel permeation chromatography (GPC) is a physical elution method in which larger components are eluted first and smaller components are eluted later depending on the size of the hydrodynamic volume of the analyzed components. Large molecules cannot enter the pores of the porous gel and pass through quickly, while small molecules can enter the pores of the gel and are retained there, allowing them to pass through slowly. The relative molecular weights are analyzed in the order of molecules that pass through the column quickly.

[0014] If the Mn1 / Mn2 ratio in the biocompatible copolymer exceeds 1.84, the powder formulation produced using such copolymer may not exhibit tissue repair effects. More specifically, the Mn1 / Mn2 ratio in the biocompatible copolymer may be 1.84 or less, 1.82 or less, 1.8 or less, 1.78 or less, 1.76 or less, or 1.75 or less. The lower limit of the Mn1 / Mn2 ratio is not particularly limited, and may be, for example, 0.5 or more, 0.55 or more, 0.6 or more, 0.65 or more, 0.7 or more, 0.75 or more, 0.8 or more, 0.85 or more, 0.9 or more, or 0.95 or more, but is not limited thereto.

[0015] In a preferred embodiment, the biocompatible copolymer satisfies both of the above conditions (1) and (2).

[0016] Specifically, the hydrophilic biocompatible polymer may be selected from the group consisting of polyethylene glycol or a derivative thereof (e.g., alkoxy- or hydroxy-polyethylene glycol), polyvinylpyrrolidone, polyvinyl alcohol, polyacrylamide, and combinations thereof, and more specifically, may be selected from the group consisting of polyethylene glycol (PEG), methoxypolyethylene glycol (mPEG), and combinations thereof. Specifically, the hydrophobic biocompatible polymer may be a polymer of an alpha (α)-hydroxy acid-derived monomer, more specifically, selected from the group consisting of polylactide, polyglycolide, poly(lactic-glycolide), polymandelic acid, polycaprolactone, polydioxan-2-one, polyamino acid, polyorthoester, polyanhydride, polycarbonate, and combinations thereof, and more specifically, selected from the group consisting of polylactide, polyglycolide, poly(lactic-glycolide), and combinations thereof.

[0017] Specifically, the number average molecular weight (Mn1) (unit: g / mol) of the hydrophilic biocompatible polymer measured by GPC may be 1,000 or more, 2,000 or more, 3,000 or more, or 4,000 or more, and may be 30,000 or less, 25,000 or less, 20,000 or less, or 15,000 or less. Specifically, the number average molecular weight (Mn2) (unit: g / mol) of the hydrophobic biocompatible polymer measured by GPC may be 500 or more, 1,000 or more, 1,500 or more, or 2,000 or more, and may be 30,000 or less, 25,000 or less, 20,000 or less, or 15,000 or less. Specifically, the total number average molecular weight of the biocompatible copolymer by GPC may be 2,000 or more, 5,000 or more, 8,000 or more, or 10,000 or more, and may be 40,000 or less, 35,000 or less, 30,000 or less, or 25,000 or less.

[0018] The powder formulation for tissue repair of the present invention may further contain, in addition to the biocompatible copolymer, one or more additives that can be commonly used in pharmaceutical powder formulations. In one embodiment, the tissue repair powder formulation of the present invention can further comprise a lyophilization aid (also called a lyophilizing agent). Specifically, the freeze-drying aid may be one or more selected from the group consisting of lactose, maltose, sucrose, trehalose, mannitol, sorbitol, maltitol, xylitol, and lactitol.

[0019] In one embodiment, the powder formulation for tissue repair of the present invention can further comprise a local anesthetic. Specifically, the local anesthetics include ambucaine, amolanone, amylocaine, benoxinate, benzocaine, betoxycaine, biphenamine, bupivacaine, butacaine, butamben, butanilicaine, butethamine, and butoxycaine. Caine (butoxycaine), carticaine, chloroprocaine, cocaethylene, cocaine, cyclomethycaine, dibucaine, dimethysoquin, dimethocaine, diperodon, dicyclonine, ecgonidine, ecgonin e), ethylchloride, etidocaine, beta-eucaine, euprocin, fenalcomine, formocaine, hexylcaine, hydroxytetracaine, isobutyl p-aminobenzoate, leucinocaine mesylate ), levoxadrol, lidocaine, mepivacaine, meprylcaine, metabutoxycaine, methylchloride, myrtecaine, naepaine, octacaine, orthocaine, oxethazaine, parethoxycaine,The antihistamine may be one or more selected from the group consisting of phenacaine, phenol, piperocaine, pyridocaine, polidocanol, pramoxine, prilocaine, procaine, propanocaine, proparacaine, propipocaine, propoxycaine, pseudococaine, pyrrocaine, ropivacaine, salicyl alcohol, tetracaine, tolycaine, trimecaine, zolamine, and salts thereof.

[0020] The powder preparation for tissue repair of the present invention may be a preparation that has been dried by freeze-drying or other drying methods (eg, spin drying) to have the properties of a powder.

[0021] Another aspect of the present invention provides a method for producing a powder formulation for tissue repair, comprising the steps of: polymerizing a monomer for a hydrophobic biocompatible polymer in the presence of a hydrophilic biocompatible polymer to produce a copolymer of a hydrophilic biocompatible polymer and a hydrophobic biocompatible polymer; and drying the produced copolymer, wherein (1) the biocompatible copolymer forms nanoparticles in the form of micelles having an average diameter of more than 20 nm and not more than 100 nm as measured by dynamic light scattering in an aqueous medium [Condition (1)]; or (2) the ratio (Mn1 / Mn2) of the number average molecular weight (Mn1) of the hydrophilic biocompatible polymer to the number average molecular weight (Mn2) of the hydrophobic biocompatible polymer in the biocompatible copolymer is 1.84 or less [Condition (2)]; or (3) the biocompatible copolymer satisfies both of Conditions (1) and (2).

[0022] In the method for producing a powder preparation for tissue repair of the present invention, the hydrophilic biocompatible polymer, hydrophobic biocompatible polymer, and biocompatible copolymer are the same as those described above. Specifically, the monomer for the hydrophobic biocompatible polymer may be an alpha (α)-hydroxy acid-derived monomer, more specifically, selected from the group consisting of lactide, glycolide, mandelic acid, caprolactone, and combinations thereof, and even more specifically, selected from the group consisting of lactide, glycolide, mandelic acid, and combinations thereof, but is not limited thereto. The step of polymerizing the monomer for the hydrophobic biocompatible polymer in the presence of the hydrophilic biocompatible polymer can be carried out according to known methods and conditions. Specifically, the biocompatible copolymer can be dried by freeze-drying or other drying methods (e.g., spin-drying, etc.), more specifically, but not limited to, freeze-drying. The freeze-drying of the biocompatible copolymer can be performed in the presence of the freeze-drying aids described above, but is not limited to this.

[0023] The powder preparation for tissue repair of the present invention dissolves easily in an aqueous medium at room temperature to form stable nanoparticles in the form of micelles with an average diameter of more than 20 nm and not more than 100 nm. After being introduced into the body, the nanoparticles self-organize to form large structures due to the hydrophobic aggregation of hydrophobic polymers in response to the influence of the internal environment, and induce collagen without being phagocytosed by macrophages, thereby demonstrating excellent tissue repair effects. In the present invention, the tissue repair effect refers to the effect of restoring skin tissue to its original state when necrosis or loss occurs in the skin tissue due to trauma, inflammation, aging, or the like. Therefore, another aspect of the present invention provides an injectable composition for tissue repair, comprising the powder formulation for tissue repair of the present invention; and a pharmaceutically acceptable carrier for injection.

[0024] The pharmaceutically acceptable injectable carrier contained in the injectable composition for tissue repair of the present invention can be any conventionally known carrier, and examples thereof include, but are not limited to, distilled water for injection, saline, 5% glucose, buffer solutions (e.g., phosphate buffer solution (PBS)), and combinations thereof. In addition to the above-mentioned components, the injectable composition for tissue repair of the present invention may further contain one or more conventional additives that can be used in injectable preparations.

[0025] Yet another aspect of the present invention provides a method for producing an injectable composition for tissue repair, which comprises mixing the powder formulation for tissue repair of the present invention and a pharmaceutically acceptable injectable carrier at room temperature. In the method for producing the injectable composition for tissue repair of the present invention, "room temperature" means 1 to 30°C, 20 to 30°C, 22 to 28°C, and more specifically 24 to 26°C (for example, 25°C). Existing powder formulations of polymeric tissue repair products require heating (e.g., the temperature must be raised between the melting point of the polymer and the boiling point of water) to be prepared in the form of an aqueous solution. However, the powder formulation for tissue repair of the present invention is easily dissolved in an aqueous medium even at room temperature, allowing the injectable composition in the form of an aqueous solution to be easily prepared and used at room temperature.

[0026] The present invention will be described in more detail below with reference to the following examples, although the examples are for illustrative purposes only and are not intended to limit the scope of the present invention. [Example]

[0027] Manufacturing Example 1: Manufacturing of powder formulation To obtain a biocompatible copolymer with a target number-average molecular weight (Mn) of 15,000 g / mol, D,L-lactide monomer was polymerized under a catalyst in the presence of methoxypolyethylene glycol (mPEG) with a number-average molecular weight (Mn1) of 9,850 g / mol (as measured by GPC). The resulting copolymer was then dried to obtain a powder formulation. GPC analysis revealed that the number-average molecular weight (Mn) of the mPEG-poly(D,L-lactide) copolymer was 15,500 g / mol. The molecular weight of the hydrophobic polymer was calculated by subtracting the molecular weight of the hydrophilic polymer from the molecular weight of the copolymer. The ratio of the number-average molecular weight (Mn1) of mPEG (the hydrophilic polymer in the copolymer) to the number-average molecular weight (Mn2) of poly(D,L-lactide) (the hydrophobic polymer) (Mn1 / Mn2) was 1.74.

[0028] Manufacturing Example 2: Manufacturing of powder formulation A powder formulation was produced in the same manner as in Production Example 1, except that the target number-average molecular weight (Mn) of the biocompatible copolymer was set to 17,000 g / mol. GPC measurement revealed that the number-average molecular weight (Mn) of the produced mPEG-poly(D,L-lactide) copolymer was 17,200 g / mol, and the molecular weight of the hydrophobic polymer was calculated by subtracting the molecular weight of the hydrophilic polymer from the measured molecular weight of the copolymer. The ratio (Mn1 / Mn2) of the number-average molecular weight (Mn1) of mPEG (the hydrophilic polymer in the copolymer) to the number-average molecular weight (Mn2) of poly(D,L-lactide) (the hydrophobic polymer) was 1.34.

[0029] Manufacturing Example 3: Manufacturing of powder formulation A powder formulation was produced in the same manner as in Production Example 1, except that the target number-average molecular weight (Mn) of the biocompatible copolymer was set to 20,000 g / mol. GPC measurement revealed that the number-average molecular weight (Mn) of the produced mPEG-poly(D,L-lactide) copolymer was 20,200 g / mol, and the molecular weight of the hydrophobic polymer was calculated by subtracting the molecular weight of the hydrophilic polymer from the measured molecular weight of the copolymer. The ratio (Mn1 / Mn2) of the number-average molecular weight (Mn2) of mPEG (the hydrophilic polymer in the copolymer) to the number-average molecular weight (Mn2) of poly(D,L-lactide) (the hydrophobic polymer) was 0.95.

[0030] Comparative Example 1 A commercial product consisting of mPEG-poly(carbohydrate)-copolymer (Miracle L, manufactured by Dexlevo) was freeze-dried and prepared as a powder, and used as Comparative Example 1.

[0031] Comparative Example 2: Preparation of powder formulation A powder formulation was produced in the same manner as in Production Example 1, except that the target number-average molecular weight (Mn) of the biocompatible copolymer was set to 12,000 g / mol. GPC measurement revealed that the number-average molecular weight (Mn) of the produced mPEG-poly(D,L-lactide) copolymer was 12,350 g / mol, and the molecular weight of the hydrophobic polymer was calculated by subtracting the molecular weight of the hydrophilic polymer from the measured molecular weight of the copolymer. The ratio (Mn1 / Mn2) of the number-average molecular weight (Mn1) of mPEG (the hydrophilic polymer in the copolymer) to the number-average molecular weight (Mn2) of poly(D,L-lactide) (the hydrophobic polymer) was 2.8.

[0032] Comparative Example 3: Preparation of powder formulation To obtain a biocompatible copolymer with a target number-average molecular weight (Mn) of 25,000 g / mol, D,L-lactide monomer was polymerized under a catalyst in the presence of methoxypolyethylene glycol (mPEG) with a number-average molecular weight (Mn1) of 20,000 g / mol (as measured by GPC). The resulting copolymer was dried to obtain a powder formulation. GPC analysis revealed that the number-average molecular weight (Mn) of the mPEG-poly(D,L-lactide) copolymer was 25,650 g / mol. The molecular weight of the hydrophobic polymer was calculated by subtracting the molecular weight of the hydrophilic polymer from the molecular weight of the copolymer. The ratio of the number-average molecular weight (Mn1) of mPEG (the hydrophilic polymer in the copolymer) to the number-average molecular weight (Mn2) of poly(D,L-lactide) (the hydrophobic polymer) (Mn1 / Mn2) was 3.5.

[0033] Comparative Example 4: Preparation of powder formulation To obtain a biocompatible copolymer with a target number-average molecular weight (Mn) of 23,000 g / mol, D,L-lactide monomer was polymerized under a catalyst in the presence of methoxypolyethylene glycol (mPEG) with a number-average molecular weight (Mn1) of 20,000 g / mol (GPC measurement). The resulting copolymer was dried to obtain a powder formulation. GPC analysis revealed that the number-average molecular weight (Mn) of the mPEG-poly(D,L-lactide) copolymer was 23,500 g / mol. The molecular weight of the hydrophobic polymer was calculated by subtracting the molecular weight of the hydrophilic polymer from the molecular weight of the copolymer. The ratio of the number-average molecular weight (Mn1) of mPEG (the hydrophilic polymer in the copolymer) to the number-average molecular weight (Mn2) of poly(D,L-lactide) (the hydrophobic polymer) (Mn1 / Mn2) was 5.7.

[0034] Comparative Example 5: Preparation of powder formulation To obtain a biocompatible copolymer with a target number-average molecular weight (Mn) of 15,000 g / mol, ε-caprolactone monomer was polymerized under a catalyst in the presence of methoxypolyethylene glycol (mPEG) with a number-average molecular weight (Mn1) of 9,800 g / mol (GPC measurement). The resulting copolymer was dried to obtain a powder formulation. GPC analysis revealed that the number-average molecular weight (Mn) of the mPEG-PCL copolymer was 15,100 g / mol. The molecular weight of the hydrophobic polymer was calculated by subtracting the molecular weight of the hydrophilic polymer from the molecular weight of the copolymer. The ratio of the number-average molecular weight (Mn1) of mPEG (the hydrophilic polymer in the copolymer) to the number-average molecular weight (Mn2) of poly(D,L-lactide) (the hydrophobic polymer) (Mn1 / Mn2) was 1.85. When the mPEG-PCL was mixed at room temperature to prepare an aqueous solution, the dispersion stability was poor, leading to the precipitation of polymer particles, making particle size analysis difficult and unreliable. Therefore, the mPEG-PCL was added to water, heated to 80°C, and mixed to prepare a polymer colloid aqueous solution, which was then diluted to a concentration of 5 wt% and subjected to particle size analysis.

[0035] Experimental Example 1: Analysis of molecular weight of polymer The number average molecular weights (Mn) of the copolymers of Production Examples 1 to 3 and Comparative Examples 1 to 5 were measured by gel permeation chromatography (GPC) under the conditions shown in the table below. The results are shown in Table 1 below.

[0036] JPEG0007775439000001.jpg66166

[0037] Experimental Example 2: Measurement of the average diameter of polymer nanoparticles in aqueous media The formulations of Preparation Examples 1 to 3 and Comparative Examples 1 to 5 were added to water for injection as an aqueous medium to prepare solutions with a concentration of 5 wt %, and the average diameter of the polymer nanoparticles formed in the aqueous medium was measured by dynamic light scattering (DLS) using a Malvern Zetasizer Nano Series 90. When the powder formulations of Preparation Examples 1 to 3 were dissolved in the aqueous medium, it was confirmed that fine-sized polymer nanoparticles, which were difficult to see with the naked eye, were formed in the aqueous medium. The results of the average diameter measurements are shown in Figure 1 and Table 1 below.

[0038] JPEG0007775439000002.jpg78166

[0039] Experimental Example 3: Confirmation of stability of aqueous solution of powder formulation The powder formulation of Preparation Example 3 was dissolved in water for injection at room temperature at a concentration of 5 wt %, and the state was observed over time to confirm the stability of the aqueous solution. The powder formulation of Preparation Example 3 was completely dissolved within 20 minutes, and no particles were observed with the naked eye. After standing for 3 hours, no significant changes occurred, and no particles were observed with the naked eye.

[0040] For comparison, a freeze-dried powder formulation of the comparative product (Miracle L) was added to water for injection at room temperature at a concentration of 5% by weight, and the state was observed over time. The dispersion of the freeze-dried powder formulation of the comparative product (Miracle L) was opaque and cloudy, and even after 3 hours, the particles had not dissolved, but had precipitated or dispersed in the water for injection.

[0041] Experimental Example 4: Verification of effectiveness as a tissue repair preparation through animal experiments The effectiveness of the powder formulation of the present invention on tissue repair was verified by animal experiments, which were carried out using 5-week-old SD rats (purchased from Orient Bio Co., Ltd.). In the animal experiments, 5-week-old SD rats were administered saline and test substances bilaterally. The rats were kept in a 24±2°C (temperature), 50±10% (relative humidity), and 12-hour lighting period, and were allowed to eat freely. As a control, physiological saline was used. As test substances, aqueous solutions (concentrations of 5%, 10%, and 20%) prepared by dissolving each of the powder formulations prepared in Preparation Examples 1 and 3 in water for injection were used. As comparison groups, aqueous solutions (20% concentration) prepared by dissolving the product of Comparative Example 1 (Miracle L) and the powder formulations of Comparative Examples 2 to 5 in water for injection were used. 100 μL of each solution was injected at a constant rate. After 6 weeks, the experimental animals were sacrificed, and the skin tissue at the sample injection site (indicated by the arrow in the upper part of Figure 2) was stained with Masson's trichrome (MT) to observe collagen formation within the tissue and evaluate the ability of new collagen biosynthesis. The results are shown in Figure 2 (lower part of Figure 2).

[0042] As can be seen from Figure 2, the aqueous solutions of the formulations of the Production Examples showed superior collagen formation compared to the comparative examples, particularly Miracle L, and it was confirmed that the formulation of Production Example 3 in particular formed a significantly larger number of collagen fibers than the comparative examples, particularly Miracle L. In other words, it was confirmed that the powder preparation according to the present invention has the advantages of being easier to transport, store and handle, and of being easily dissolved in aqueous media at room temperature, compared to comparative examples, particularly Miracle L, and that after being introduced into the body, it induces collagen formation more efficiently and exhibits excellent tissue repair effects.

Claims

1. A powder preparation for tissue repair comprising a biocompatible copolymer which is a copolymer of a hydrophilic biocompatible polymer and a hydrophobic biocompatible polymer, The biocompatible copolymer satisfies the following condition (2): (2) The ratio (Mn1 / Mn2) of the number average molecular weight (Mn1) of the hydrophilic biocompatible polymer to the number average molecular weight (Mn2) of the hydrophobic biocompatible polymer in the biocompatible copolymer is 0.8 or more and 1.84 or less [Condition (2)] Fulfilling the hydrophilic biocompatible polymer is selected from the group consisting of polyethylene glycol (PEG), methoxypolyethylene glycol (mPEG), polyvinyl alcohol, and combinations thereof; The hydrophobic biocompatible polymer is selected from the group consisting of polylactide, polyglycolide, poly(lactic-glycolide), and combinations thereof. Powder formulation for tissue repair.

2. The biocompatible copolymer further satisfies the following condition (1): (1) The biocompatible copolymer forms nanoparticles in the form of micelles having an average diameter of more than 20 nm and not more than 100 nm as measured by dynamic light scattering in an aqueous medium.

2. The powder preparation for tissue repair according to claim 1, which satisfies the above requirements.

3. 2. The powder preparation for tissue repair according to claim 1, wherein the hydrophilic biocompatible polymer is selected from the group consisting of polyethylene glycol (PEG), methoxypolyethylene glycol (mPEG), and combinations thereof.

4. 2. The powder preparation for tissue repair according to claim 1, wherein the number average molecular weight of the hydrophilic biocompatible polymer determined by gel permeation chromatography is 1,000 g / mol to 30,000 g / mol.

5. 2. The powder preparation for tissue repair according to claim 1, wherein the number average molecular weight of the hydrophobic biocompatible polymer determined by gel permeation chromatography is 500 g / mol to 30,000 g / mol.

6. 2. The powder preparation for tissue repair according to claim 1, wherein the number average molecular weight of the biocompatible copolymer determined by gel permeation chromatography is 2,000 g / mol to 40,000 g / mol.

7. The powder formulation for tissue repair according to claim 1, further comprising a freeze-drying aid.

8. 8. The powder preparation for tissue repair according to claim 7, wherein the freeze-drying aid is one or more selected from the group consisting of lactose, maltose, sucrose, trehalose, mannitol, sorbitol, maltitol, xylitol and lactitol.

9. 2. The powder formulation for tissue repair according to claim 1, further comprising a local anesthetic.

10. The local anesthetic may be ambucaine, amolanone, amylocaine, benoxinate, benzocaine, betoxycaine, biphenamine, bupivacaine, butacaine, butamben, butanilicaine, butethamine, or butox ycaine, carticaine, chloroprocaine, cocaethylene, cocaine, cyclomethycaine, dibucaine, dimethysoquin, dimethocaine, diperodon, dicyclonine, ecgonidine, ecgonine, ethyl chloride chloride), etidocaine, beta-eucaine, euprocin, fenalcomine, formocaine, hexylcaine, hydroxytetracaine, isobutyl p-aminobenzoate, leucinocaine mesylate, levoxadrol, lidocaine, mepivacaine, meprylcaine, metabutoxycaine, methyl chloridechloride), myrtecaine, naepaine, octacaine, orthocaine, oxethazaine, parethoxycaine, phenacaine, phenol, piperocaine, pyridocaine, polidocanol, pramoxine, prilocaine, procaine, propanocaine, proparacaine, propipocaine, propoxycaine, pseudococaine, pyrrocaine, ropivacaine, salicyl alcohol 10. The powder preparation for tissue repair according to claim 9, wherein the powder preparation is one or more selected from the group consisting of tetracaine, tricaine, trimecaine, zolamine, and salts thereof.

11. A method for producing a powder preparation for tissue repair, comprising the steps of: polymerizing a monomer for a hydrophobic biocompatible polymer in the presence of a hydrophilic biocompatible polymer to produce a biocompatible copolymer, which is a copolymer of a hydrophilic biocompatible polymer and a hydrophobic biocompatible polymer; and drying the produced biocompatible copolymer, the ratio (Mn1 / Mn2) of the number average molecular weight (Mn1) of the hydrophilic biocompatible polymer to the number average molecular weight (Mn2) of the hydrophobic biocompatible polymer in the biocompatible copolymer is 0.8 or more and 1.84 or less; the hydrophilic biocompatible polymer is selected from the group consisting of polyethylene glycol (PEG), methoxypolyethylene glycol (mPEG), polyvinyl alcohol, and combinations thereof; The hydrophobic biocompatible polymer is selected from the group consisting of polylactide, polyglycolide, poly(lactic-glycolide), and combinations thereof; Method for producing a powder formulation for tissue repair.

12. The method for producing a powder preparation for tissue repair according to claim 11, wherein the monomer for the hydrophobic biocompatible polymer is selected from the group consisting of lactide, glycolide, and combinations thereof.

13. The powder preparation for tissue repair according to any one of claims 1 to 10; and a pharmaceutically acceptable injectable carrier; An injectable composition for tissue repair comprising:

14. A method for producing an injectable composition for tissue repair, comprising mixing the powder formulation for tissue repair according to any one of claims 1 to 10 and a pharmaceutically acceptable injectable carrier at room temperature.

Images